Mo1176 Autologous Hematopoietic Stem Cell Transplantation in Refractory Crohn's Disease: Feasibility and Toxicity

G A A b st ra ct s diagnosis of cancer was 10 (range 1-38). IMM used after the diagnosis of cancer included thiopurines in 12 (AZA n= 8 ; 6MP n4), anti-TNFs in 3 (ADA n=.2; local IFX n=1). Among the 15 IBD patients treated with IMM after the diagnosis of neoplasia, cancer involved: thyroid (n=4), skin (n=2; 1 basal cell carcinoma, 1 spinal cell carcinoma); breast (n=2), colon (n=2), prostatic cancer (n=2) lymphoma (HL n=1), seminoma (n=1), carcinoid of the appendix (n=1). The time interval between the diagnosis of cancer and IMM was 6 yrs (range 1-26). After a median follow up from the diagnosis of cancer of 10 yrs (range 3-30), none of the 15 IBD patients treated with IMM after the diagnosis of cancer showed recurrence of cancer, or had a cancer-related death. Death was observed in 1 CD patient, due to cirrhosis. CONCLUSIONS. In a preliminary retrospective study, treating IBD patients with thiopurines or anti-TNFs after a diagnosis of cancer currently appeared not to determine a recurrence of the neoplastic disease. Larger prospective longitudinal studies are needed to further address this open issue in IBD.